Table 1 Baseline clinical characteristics of the patients
Variables | CoQ10 + TMZ group (n = 75) | Control group (n = 75) | p value |
|---|---|---|---|
Age (years) | 61.75 ± 9.15 | 63.52 ± 7.88 | 0.205 |
Female, n (%) | 34 (45.33) | 33 (44.00) | 0.870 |
BMI (kg/m2) | 26.30 ± 4.06 | 25.43 ± 2.85 | 0.131 |
Hypertension, n (%) | 32 (42.67) | 35 (46.67) | 0.622 |
Diabetes mellitus, n (%) | 31 (41.33) | 34 (45.33) | 0.621 |
Hyperlipidemia, n (%) | 29 (38.67) | 26 (34.67) | 0.611 |
Smoking, n (%) | 39 (52.00) | 41 (54.67) | 0.743 |
LVEF (%) | 56.18 ± 6.53 | 54.62 ± 5.68 | 0.121 |
AMI, n (%) | 13 (17.33) | 10 (13.33) | 0.479 |
Previous myocardial infarction n (%) | 11 (14.67) | 8 (20.67) | 0.461 |
Laboratory results | |||
Hemoglobin (g/L) | 125.01 ± 9.28 | 126.25 ± 9.72 | 0.426 |
Glycosylated hemoglobin (%) | 6.08 ± 0.88 | 6.26 ± 1.00 | 0.229 |
Low-density lipoprotein cholesterol (mg/dL) | 118.79 ± 18.45 | 117.75 ± 21.39 | 0.750 |
Medications, n (%) | |||
β-blocker | 52 (69.33) | 49 (65.33) | 0.601 |
ACEI/ARB | 42 (56.00) | 38 (50.67) | 0.513 |
Statins | 67 (89.33) | 71 (94.67) | 0.229 |
Diuretics | 6 (8.00) | 8 (10.67) | 0.575 |
Nitrate | 40 (53.33) | 46 (61.33) | 0.322 |
Calcium-channel blocker | 32 (42.67) | 38 (50.67) | 0.326 |
Proton pump inhibitors | 20 (26.67) | 16 (21.33) | 0.444 |
PCI, n (%) | 39 (52.00) | 36 (48.00) | 0.624 |
Use of bivalirudin, n (%) | 26 (34.67) | 21 (28.00) | 0.379 |
Use of GPI, n (%) | 15 (20.00) | 16 (21.33) | 0.840 |
Volume of CM (mL) | 136.40 ± 68.57 | 130.13 ± 63.79 | 0.563 |
CM ≥ 160 mL, n (%) | 35 (46.67) | 30 (40.00) | 0.410 |
Hydration volume (mL) | 1754.40 ± 358.41 | 1716.32 ± 238.30 | 0.445 |